Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study - PubMed (original) (raw)

Clinical Trial

Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study

M J O'Connell et al. J Clin Oncol. 1986 Feb.

Abstract

Twenty patients with disseminated favorable histology non-Hodgkin's lymphomas (16 patients) or chronic lymphocytic leukemia (four patients) who had not received previous chemotherapy were treated with recombinant leukocyte A interferon (IFL-rA) (Hoffmann-La Roche, Nutley, NJ). Treatment was administered in a moderate dose (12 X 10(6) U/m2) by intramuscular (IM) injection three times weekly for 8 weeks, followed by weekly maintenance therapy for an additional 16 weeks in patients responding to therapy. Five patients with stable disease at 8 weeks received four additional weeks of three-times-weekly treatment at an escalated dose (25 X 10(6) U/m2). Interferon was tolerated without severe toxicity by most patients, although treatment was discontinued prematurely due to side effects in four patients. Objective tumor responses (one complete response [CR] and six partial responses [PRs]) were seen in seven of 16 patients with lymphoma (44%). One of four patients with chronic lymphocytic leukemia also experienced a PR. Median time-to-progression from initiation of therapy among responding patients was 26 + weeks (range, 7 + to 84 + weeks). This study has demonstrated single agent antitumor activity of IFL-rA given in a tolerable outpatient dosage regimen in patients with advanced favorable histology non-Hodgkin's lymphomas, and serves as a basis for further trials of IFL-rA combined with chemotherapy as initial therapy for such patients in the future.

PubMed Disclaimer

Cited by

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.
Rohatiner A, Radford J, Deakin D, Earl H, Love SB, Price O, Wilson A, Lister TA. Rohatiner A, et al. Br J Cancer. 2001 Jul 6;85(1):29-35. doi: 10.1054/bjoc.2001.1822. Br J Cancer. 2001. PMID: 11437398 Free PMC article. Clinical Trial.
Management of chronic lymphocytic leukaemia.
Kalil N, Cheson BD. Kalil N, et al. Drugs Aging. 2000 Jan;16(1):9-27. doi: 10.2165/00002512-200016010-00002. Drugs Aging. 2000. PMID: 10733261 Review.
The role of interferon as maintenance therapy in malignant lymphoma.
Avilés A. Avilés A. Med Oncol. 1997 Sep-Dec;14(3-4):153-7. doi: 10.1007/BF02989643. Med Oncol. 1997. PMID: 9468038 Review.
Low-grade lymphomas: new entities and treatment concepts.
Hagemeister FB. Hagemeister FB. Med Oncol. 1995 Sep;12(3):131-42. doi: 10.1007/BF01571190. Med Oncol. 1995. PMID: 8852395 Review.
A phase I trial of intrapleural recombinant human interferon alpha (rHuIFN alpha 2b) in patients with malignant pleural effusions.
Bhatia A, Rice TW, McLain D, Herzog P, Budd GT, Murthy S, Kirby TJ, Bukowski RM. Bhatia A, et al. J Cancer Res Clin Oncol. 1994;120(3):169-72. doi: 10.1007/BF01202197. J Cancer Res Clin Oncol. 1994. PMID: 8263014 Clinical Trial.

Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study - PubMed (original) (raw)